Morteza Entezari1, Saeed Karimi2, Hamid Ahmadieh3, Amir Hossein Mahmoudi4, Hamid Parhizgar4, Mehdi Yaseri5. 1. Ophthalmic Research Center, Department of Ophthalmology, Imam Hossein Medical Center, Shahid Beheshti Medical Sciences, Shahid Madani Ave., Tehran, Iran. entmort@hotmail.com. 2. Ophthalmic Research Center, Department of Ophthalmology, Torfe Hospital, Shahid Beheshti Medical Sciences, Tehran, Iran. 3. Ophthalmic Research Center, Department of Ophthalmology, Labbafinejad Hospital, Shahid Beheshti Medical Sciences, Tehran, Iran. 4. Ophthalmic Research Center, Department of Ophthalmology, Razi Hospital, Tehran, Iran. 5. Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran, Iran.
Abstract
PURPOSE: This study reports the findings in a large series of patients with acute bacterial endophthalmitis after intravitreal injection of bevacizumab (IVB) in two eye hospitals. METHODS: Medical records were reviewed for patients who presented with acute fulminant endophthalmitis in one or two eyes following intravitreal injection of bevacizumab from two separate batches in two eye hospitals. RESULTS: Twenty-eight eyes of 21 patients presented with acute endophthalmitis 12-48 hours after IVB injection. Cultures from the eyes and the vials were positive for E. coli and Citrobacter, each in one of the hospitals. All patients were initially treated with topical, intravitreal, and systemic antibiotics. Twenty-four eyes underwent pars plana vitrectomy. Best corrected visual acuity (BCVA) was 1.27 ± 0.89 logMAR before IVB injecti,on which decreased to 2.80 ± 0.45 LogMAR after presentation of endophthalmitis and 2.12 ± 0.97 logMAR three months after IVB injection. Final visual acuity was found to be no light perception in four eyes. CONCLUSIONS: This large outbreak of E.coli and Citrobacter endophthalmitis occurred after intravitreal injection of counterfeit bevacizumab. Visual outcomes were very poor.
PURPOSE: This study reports the findings in a large series of patients with acute bacterial endophthalmitis after intravitreal injection of bevacizumab (IVB) in two eye hospitals. METHODS: Medical records were reviewed for patients who presented with acute fulminant endophthalmitis in one or two eyes following intravitreal injection of bevacizumab from two separate batches in two eye hospitals. RESULTS: Twenty-eight eyes of 21 patients presented with acute endophthalmitis 12-48 hours after IVB injection. Cultures from the eyes and the vials were positive for E. coli and Citrobacter, each in one of the hospitals. All patients were initially treated with topical, intravitreal, and systemic antibiotics. Twenty-four eyes underwent pars plana vitrectomy. Best corrected visual acuity (BCVA) was 1.27 ± 0.89 logMAR before IVB injecti,on which decreased to 2.80 ± 0.45 LogMAR after presentation of endophthalmitis and 2.12 ± 0.97 logMAR three months after IVB injection. Final visual acuity was found to be no light perception in four eyes. CONCLUSIONS: This large outbreak of E.coli and Citrobacter endophthalmitis occurred after intravitreal injection of counterfeit bevacizumab. Visual outcomes were very poor.
Authors: Mei Hong Tan; Ian L McAllister; Mark E Gillies; Nitin Verma; Gayatri Banerjee; Lynne A Smithies; Wan-Ling Wong; Tien Y Wong Journal: Am J Ophthalmol Date: 2013-10-07 Impact factor: 5.258
Authors: Stephan Michels; Philip J Rosenfeld; Carmen A Puliafito; Erin N Marcus; Anna S Venkatraman Journal: Ophthalmology Date: 2005-06 Impact factor: 12.079
Authors: Kevin Pozsgai; Gergő Szűcs; Anikó Kőnig-Péter; Orsolya Balázs; Péter Vajda; Lajos Botz; Róbert György Vida Journal: Front Pharmacol Date: 2022-09-06 Impact factor: 5.988